Cytomegalovirus infection: An Indian perspective

Indian Journal of Medical Microbiology

Volumn 27, Issue 1, 2009, Pages 3-11

  Chakravarti, A ^a   Kashyap, B ^a   Matlani, M ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Congenital; Cytomegalovirus; Latency; Primary; Recurrent

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; BLOOD TRANSFUSION; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INDIA; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM CARE; MIXED INFECTION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEWBORN INFECTION; PHENOTYPE; PREGNANT WOMAN; PROPHYLAXIS; PUBLIC HEALTH PROBLEM; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; RETINITIS; REVIEW; TREATMENT DURATION; VIRUS DETECTION; VIRUS REPLICATION;

EID: 59049097314     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Chakravarty A, Kashyap B, Rathi K. The seroepidemiological study on cytomegalovirus in women of childbearing age with special reference to pregnancy and maternal-fetal transmission. Indian J Pathol Microbiol 2005;48:518-21.
2. Sheevani, Jindal N, Aggarwal A. A pilot seroepidemiological study of cytomegalovirus infection in women of childbearing age. Indian J Med Microbiol 2005;23:34-6.
3. Gandhoke I, Aggarwal R, Lal S, Khare S. Congenital CMV infection in symptomatic infants in Delhi and surrounding areas. Indian J Pediatr 2006;73:1095-7.
4. Azam AZ, Vial Y, Fawer CL, Zufferey J, Hohlfeld P. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 2001;97:443-8.
5. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002;15:680-715.
6. Peckham C, Tookey P, Logan S, Glaquinto C. Screening options for prevention of congenital cytomegalovirus infection. J Med Screen 2001;8:119-24.
7. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-7.
8. Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999;104:55-60.
9. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72.
10. Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000;70:1166-74.
11. Sagedal S, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005;11:518-30.
12. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of HCMV DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997;176:1484-90.
13. Ho M. Immunology of cytomegalovirus: Immunosuppressive effects during infections. Birth Defects Orig Artic Ser 1984;20:131-47.
14. Sakhuja V, Jha V, Joshi K. Cytomegalovirus disease among renal transplant recipients in India. Nephrology 2002;7:125-9.
15. Finny GJ, Mathews V, Abraham P, Abraham M, Chandy M, Srivastava A, et al. A pilot study on the role of cytomegalovirus and human herpesvirus-6 infections in Indian bone marrow transplant recipients. Indian J Med Res 2001;114:39-46.
16. Kaur P, Basu S. Transfusion-transmitted infections: Existing and emerging pathogens. J Postgrad Med 2005;51:146-51.
17. Kothari A, Ramachandran VG, Gupta P. Cytomegalovirus infection in neonates following exchange transfusion. Indian J Pediatr 2006;73:519-21.
18. Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Seroprevalence of Cytomegalovirus among Voluntary Blood Donors in Delhi, India. J Health Popul Nutr 2002;20:348-51.
19. Mujtaba S, Varma S, Sehgal S. Cytomegalovirus co-infection in patients with HIV/AIDS in north India. Indian J Med Res 2003;117:99-103.
20. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:585-94.
21. Kestelyn PG, Cunningham ET. HIV/AIDS and blindness. Bull World Health Organ 2001;79:208-13.
22. Biswas J, Madhavan HN, George AE, Kumaraswamy N, Solomon S. Ocular lesions associated with HIV infection in India: A series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol 2000;129:9-15.
23. Bodéus M, Goubau P. Predictive value of maternal IgG avidity for congenital human cytomegalovirus infection. J Clin Virol 1999;12:3-8.
24. Chakravarti A, Kashyap B, Wadhwa A. Relationship of IgG avidity index and IgM levels for the differential diagnosis of primary from recurrent cytomegalovirus infections. Iran J Allergy Asthma Immunol 2007;6:197-201.
25. Shoby CT, Soloman R, Kuruvilla KA, Jana AK, Abraham M, Finny GJ, et al. Human cytomegalovirus perinatal infections in a tertiary care setting. Indian Pediatr 2002;39:561-4.
26. Abraham M, Abraham P, Jana AK, Kuruvilla KA, Cherian T, Moses PD, et al. Serology in congenital infections: Experience in selected symptomatic infants. Indian Pediatr 1999;36:697-700.
27. Priya K, Madhavan HN. Diagnostic value of enzyme linked immuno-sorbent assay for cytomegalovirus disease. J Postgrad Med 2002;48:176-8.
28. Dar L. Identifying human cytomegalovirus genotypes and defining their clinical significance. Indian J Med Res 2007;126:99-100.
29. Sowmya P, Dhanya V, Madhavan HN, Therese KL. Comparative efficacy of PCR-based restriction fragment length polymorphism (RFLP) and multiplex PCR for glycoprotein B (gB) genotyping of human cytomegalovirus. Indian J Med Res 2007;126:122-7.
30. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:2032-6.
31. Boeckh M, Boivin G. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications. Clin Microbiol Rev 1998;11:533-54.
32. Cariani E, Pollara CP, Valloncini B, Perandin F, Bonfanti C, Manca N. Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients. BMC Infect Dis 2007;7:138.
33. Seropian S, Ferguson D, Salloum D, Cooper E, Landry ML. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplant 1998;22:507-9.
34. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002;3:746-52.
35. Machida U, Kami M, Fukui T, Kazuyama Y, Kinoshita M, Tanaka Y, et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol 2000;38:2536-42.
36. Herrmann B, Larsson VC, Rubin CJ, Sund F, Eriksson BM, Arvidson J, et al. Comparison of a duplex quantitative real-time PCR assay and the COBAS amplicor CMV monitor test for detection of cytomegalovirus. J Clin Microbiol 2004;42:1909-14.
37. Emery VC. Prophylaxis for CMV should not now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001;11:83-6.
38. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001;3:20-4.
39. Das A. Cytomegalovirus infection in solid organ transplantation: Economic implications. Pharmacoeconomics 2003;21:467-75.
40. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002;35:866-72.
41. Isada CM, Yen-Lieberman B, Lurain NS, Schilz R, Kohn D, Longworth DL, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection. Transpl Infect Dis 2002;4:189-94.
42. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-9.
43. Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000;96:3286-9.
44. Drew WL. Ganciclovir resistance: A matter of time and titre. Lancet 2000;356:609-10.
45. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999;12:286-97.
46. Wolf DG, Yaniv I, Honigman A, Kassis I, Schonfeld T, Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 1998;178:535-8.
47. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001;32:742-51.
48. De Clercq E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J Antimicrob Chemother 2003;51:1079-83.
49. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Kamil E. Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: Monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. Am J Transplant 2002;2:671-3.
50. Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001;183:333-7.
51. Schleiss M. Progress in Cytomegalovirus vaccine development. Herpes 2005;12:66-75.
52. Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 2006;12:26-33.